M&A

Innovator drug deals involving Chinese biopharma reach $41.5 billion as licensing overtakes M&A for pipeline expansion, notes…

GlobalData data shows a 46.9% drop in deal value and a 21.4% decline in venture capital investments year-on-year

The basket acquired comprises 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA

Consolidation has emerged as a major trend as the pharma industry seeks new avenues of growth and looks to expand its existing…

BSV’s 2500+ employees to join Mankind Pharma 

This deal expands DKSH to life science business in the Asia Pacific

Veeda expands its reach to major geographies and adds capabilities of late-stage clinical trial execution with strong focus on…

Expands its business in the UK market, aiming to expand its product portfolio

The merged platform to comprise three distinct business units – Pharma CDMO, Spec Chem CDMO, and API+ (inclusive of formulations)

Deal includes clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and…